| Authors | Hayley, A.C. Downey, L.A. Hansen, G. Dowell, A. Savins, D. Buchta, R. Catubig, R. Houlden, R. Stough, C.K.K. |
|---|---|
| Type | Journal Article (Original Research) |
| Journal | Forensic Science International |
| PubMed ID | 29408718 |
| Year of Publication | 2018 |
| URL | https://www.ncbi.nlm.nih.gov/pubmed/29408718 |
| DOI | /10.1016/j.forsciint.2017.12.033 |
| Abstract | Hemp-derivative (Cannabis sativa L.) food products containing trace levels of Delta-9-tetrahydrocannabinol (THC) are proposed for consumption in Australia and New Zealand; however, it is unclear whether use of these products will negatively affect existing drug screening protocols. This double-blind, within-subjects, cross-over trial assessed 35 adults (17 male; 18 female), aged 22-52 years [Mean=30.7, Standard Deviation (S.D)+/-7.6]. Low dose THC oil [5mL bearer sesame oil containing 10mg/kg THC (0.046mg THC per 5mL dose)]; high dose THC oil [5mL bearer sesame oil containing 20mg/kg THC (0.092mg THC per 5mL dose)]; and a placebo oil (THC negative) was consumed during a three-week protocol. The Securetec Drugwipe((R)) II Twin device assessed THC presence (cut-off 20ng/mL) in oral fluid at baseline, at 5, 30, 60, 120 and 240min post-treatment. Blood was drawn at baseline, 30, 120 and 240min post-treatment, and urine at baseline and 240min post-treatment. No THC was detected in oral fluid, blood or urine samples at any time-point following consumption of the low or high THC dose. Trace concentrations of 11-nor-Delta9-tetrahydrocannabinol-9-carboxylic acid (THCa) were detected in blood 4-h after consumption of the high THC treatment (M=0.0001mg/L) and in urine at 4-h post consumption of both low and high THC treatments (M=0.0001mg/L and 0.0004mg/L, respectively). Consumption of low-content THC oil does not result in positive biological assessments. It is therefore highly unlikely that ingestion of products containing these levels of THC will negatively impact existing region-specific drug driving enforcement protocols. |
http://www.ibas.org.au/what-we-do/publications/3872953
Each year in Australia 260 people sustain a SCI, with over half losing full function in their arms and legs (quadriplegia). In addition to the primary disability, there is a very high rate of Obstructive...
Sleep apnea is a condition where breathing is abnormal during sleep. There are two main forms of sleep apnea: obstructive and central. For obstructive sleep apnea, breathing is reduced because the airway...
NTC RELEASES 'WORLD FIRST' HEAVY VEHICLE DRIVER FATIGUE STUDY
The National Transport Commission (NTC) and the Cooperative Research Centre for Alertness, Safety and Productivity (Alertness CRC) have released the results of what is hailed as a world-first study into heavy vehicle driver fatigue.
AAMRI ELECTION STATEMENT RELEASED ON 25TH MARCH 2019
AAMRI released its election statement calling on politicians to commit to three main priorities: ensuring the MRFF reaches $20 billion by 2020-21, provide continued strong support for the NHMRC, and develop sustainable and rewarding career pathways.
IBAS DIRECTOR ANNA BURKE UNVEILS HER PORTRAIT AT CANBERRA'S PARLIAMENT HOUSE
Anna Burke had barely got into the swing of her speech at the unveiling of her portrait at Canberra's Parliament House when the ringing of bells caused half her audience to hurry away
NATIONAL STUDY OFFERS HOPE FOR BREATHLESSNESS
A national medication study is aiming to help thousands of Australians who struggle every day with shortness of breath
© 2019 Institute for Breathing and Sleep. All Rights Reserved.
Powered by Helmut Design | Manage
